AbCellera Biologics Inc. (ABCL)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 9.08 |
| Open | 9.12 |
| Bid | 8.60 x 1800 |
| Ask | 8.78 x 1000 |
| Day's range | 8.51 - 9.12 |
| 52-week range | 8.51 - 55.22 |
| Volume | |
| Avg. volume | 1,979,438 |
| Market cap | 2.433B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 13.42 |
| EPS (TTM) | 0.64 |
| Earnings date | 28 Mar 2022 - 01 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.88 |
- Simply Wall St.
Shareholders in AbCellera Biologics (NASDAQ:ABCL) are in the red if they invested a year ago
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
- Business Wire
AbCellera Announces Changes to Its Board of Directors
VANCOUVER, British Columbia, December 07, 2021--AbCellera Announces Changes to Its Board of Directors
- Business Wire
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
VANCOUVER, British Columbia, December 03, 2021--AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized for Emergency Use in COVID-19 Patients Under the Age of 12
© 2022 Yahoo. All rights reserved.
